Post Splenectomy Infections After Surgery for Peritoneal Malignancies (OPSI)

Last updated: November 25, 2024
Sponsor: Hampshire Hospitals NHS Foundation Trust
Overall Status: Active - Recruiting

Phase

N/A

Condition

Peritoneal Cancer

Malignant Ascites

Treatment

Questionnaire, interview or observation study

Clinical Study ID

NCT05718726
SPON-BM-1220
  • Ages 18-79
  • All Genders

Study Summary

The spleen is involved in maintaining immunity and plays an important role in the elimination of encapsulated bacteria and parasites. Patients who undergo splenectomy in conjunction with complete CRS for peritoneal malignancy are at risk of overwhelming post-splenectomy infections post-operatively. These patients are therefore administered vaccinations to lower the risk of infections but as they do not completely eliminate the risk, patients are also prescribed prophylactic antibiotics without clear evidence that they are useful in preventing OPSI. The use of prophylactic antibiotics is not without risk with potential short and long-term risks including resistance, interaction with other medication, clostridium difficile infections, fungal infections, other changes to the microbiome and cost. This study will investigate the incidence of OPSI post splenectomy and assess compliance with prophylactic antibiotics. This is an observational study where consented patients will be telephoned at fixed time points which are 1,6,12 weekly and 6 monthly for a period of five years post-operatively. As part of routine care patients will be telephoned by the clinical nurse specialist at weeks 1,6 and 12. In addition to this the research nurse will telephone the patient 6 monthly for a period of 5 years and complete a questionnaire. The research nurse will complete the questionnaire during each telephone call and this should not take more than 20 minutes. At the start of the telephone call, consent will be confirmed each time and the research nurse will check that the patient is still happy to participate before going ahead.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients aged >18 and <80 years Patients capable of providing informed consentPatients who have a splenectomy in conjunction with complete cytoreductive surgery (CRS) for any pathology

Exclusion

Exclusion Criteria:

  • Patients who are <18 and >80 Patients who do not provide informed consent Patientson immunosuppression therapy

Study Design

Total Participants: 300
Treatment Group(s): 1
Primary Treatment: Questionnaire, interview or observation study
Phase:
Study Start date:
March 25, 2021
Estimated Completion Date:
February 01, 2031

Connect with a study center

  • The Peritoneal Malignancy Institute, Hampshire Hospitals NHS Foundation Trust

    Basingstoke, Hampshire Rg24 9NN
    United Kingdom

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.